Results 1 to 10 of about 143,942 (291)

Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients [PDF]

Clinical and Molecular Hepatology, 2022
Background/Aims Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic dysfunction. Among the multiple factors, genetic variation acts as important modifiers.
Wen-Yue Liu, Xiaofang Zhang, Gang Li, Liang-Jie Tang, Pei-Wu Zhu, Rafael S. Rios, Kenneth I. Zheng, Hong-Lei Ma, Xiao-Dong Wang, Qiuwei Pan, Robert J. de Knegt, Luca Valenti, Mohsen Ghanbari, Ming-Hua Zheng   +13 more
doaj   +1 more source

Additive effect of non-alcoholic fatty liver disease on metabolic syndrome-related endothelial dysfunction in hypertensive patients [PDF]

, 2016
Metabolic syndrome (MS) is characterized by an increased risk of incident diabetes and cardiovascular (CV) events, identifying insulin resistance (IR) and endothelial dysfunction as key elements.
Caroleo B, Cimellaro A, Maio R, Perticone F, Perticone M, Sciacqua A, Sesti G   +6 more
core   +6 more sources

Imaging biomarkers of NAFLD, NASH, and fibrosis

Molecular Metabolism, 2021
Background: Non-alcoholic fatty liver disease (NAFLD) is a clinicopathologic entity that requires a liver biopsy assessment to diagnose the progressive form of NAFLD called non-alcoholic steatohepatitis (NASH).
Veeral Ajmera, Rohit Loomba
doaj   +1 more source

Characteristic gene expression in the liver monocyte-macrophage-DC system is associated with the progression of fibrosis in NASH

Frontiers in Immunology, 2023
BackgroundThe monocyte-macrophage-dendritic cell (DC) (MMD) system exerts crucial functions that may modulate fibrogenesis in nonalcoholic steatohepatitis (NASH).
Xiaoxiao Wang, Zilong Wang, Baiyi Liu, Rui Jin, Yuyun Song, Ran Fei, Xu Cong, Rui Huang, Xiaohe Li, Jia Yang, Lai Wei, Huiying Rao, Feng Liu   +12 more
doaj   +1 more source

Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models

Frontiers in Medicine, 2023
BackgroundNon-alcoholic fatty liver disease (NAFLD) is a global commonly occurring liver disease. However, its exact pathogenesis is not fully understood.
Xiao-Xiao Wang, Rui Jin, Xiao-He Li, Qiang Yang, Xiao Teng, Fang-Fang Liu, Nan Wu, Hui-Ying Rao, Feng Liu   +8 more
doaj   +1 more source

Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma [PDF]

Clinical and Molecular Hepatology, 2023
Background/Aims Cirrhosis is the most important risk factor of hepatocellular carcinoma (HCC), and patients with cirrhosis are recommended to receive semiannual surveillance for early HCC detection.
Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang   +7 more
doaj   +1 more source

Appendicular Skeletal Muscle Index and HbA1c Evaluate Liver Steatosis in Patients With Metabolic Associated Fatty Liver Disease

Frontiers in Medicine, 2022
Background and Aim(s)Liver steatosis, as the main feature of metabolic associated fatty liver disease (MAFLD), was associated with the progression of liver fibrosis and metabolic syndrome, which needed to be estimated accurately.
Rui Jin, Xiaoxiao Wang, Xiaohe Li, Jia Yang, Baiyi Liu, Lai Wei, Feng Liu, Huiying Rao   +7 more
doaj   +1 more source

LAMP3 expression in the liver is involved in T cell activation and adaptive immune regulation in hepatitis B virus infection

Frontiers in Immunology, 2023
BackgroundThe disease burden caused by chronic hepatitis B virus (HBV) infection is still heavy, and the current treatment scheme has not achieved a complete cure. Changes in natural and adaptive immunity usually accompany chronic HBV infection.
Zilong Wang, Xiaoxiao Wang, Rui Jin, Feng Liu, Huiying Rao, Lai Wei, Hongsong Chen, Bo Feng   +7 more
doaj   +1 more source

Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. [PDF]

, 2014
ObjectiveNonalcoholic fatty liver disease (NAFLD) affects 9.6% of children and may put these children at elevated risk of high blood pressure and subsequent cardiovascular morbidity and mortality.
Behling, Cynthia, Donithan, Michele, Hallinan, Erin K, Newton, Kimberly P, Nonalcoholic Steatohepatitis Clinical Research Network, Schwimmer, Jeffrey B, Tonascia, James, Xanthakos, Stavra A, Zepeda, Anne   +8 more
core   +10 more sources

Mid‐upper arm circumference is associated with liver steatosis and fibrosis in patients with metabolic‐associated fatty liver disease: A population based observational study

Hepatology Communications, 2022
Metabolic‐associated fatty liver disease (MAFLD) is a series of liver diseases based on liver steatosis and metabolic disorders. Steatosis, as the core factor in MAFLD diagnosis, and fibrosis, as the major determinant of adverse outcomes of MAFLD, need ...
Xiaoxiao Wang, Xiaohe Li, Rui Jin, Jia Yang, Rui Huang, Lai Wei, Feng Liu, Huiying Rao   +7 more
doaj   +1 more source